

S2 Table. Subsequent treatment after tumor progression

Treatment	IP plus simvastatin	IP	p-value^{a)}
Second-line treatment			0.111
Irinotecan plus platinum	4 (6.5)	6 (9.5)	
Etoposide plus platinum	31 (50.0)	25 (39.7)	
Paclitaxel	0	4 (6.3)	
Adriamycin combination	3 (4.8)	7 (11.1)	
Anti-PD(L) inhibitor	3 (4.8)	3 (4.8)	
Others	6 (9.7)	1 (1.6)	
none	15 (24.2)	17 (27.0)	

Values are presented as number (%). IP, irinotecan plus cisplatin; PD(L), programmed death ligand.

^{a)}Tested with Pearson's χ^2 test or Fisher's exact test.